iCAD is highlighting positive clinical results for its Xoft Axxent electronic brachytherapy system that were presented at this week's American Society for Radiology Oncology (ASTRO) meeting in San Antonio.
The study was a long-term follow-up of clinical results with Axxent for intraoperative radiation therapy (IORT) performed at the time of breast-conserving surgery. The principal investigator was Dr. Nisar Syed of Long Beach Memorial Medical Center, University of California Medical Center, and Harbor-UCLA School of Medicine.
The trial enrolled 1,201 patients from May 2012 to July 2018 at 28 institutions worldwide and in the U.S. At a median follow-up of two years, fewer than 1% of patients experienced regrowth of their cancer (ipsilateral recurrence) or developed new primary cancers in the contralateral breast. Patients tolerated the treatment well, with grade 3, 4, and 5 adverse events occurring in only 37 patients. Mean treatment time with Axxent was 10.5 minutes.
The results indicate that a single fraction of radiation with Axxent electronic brachytherapy yields excellent results in patients with early-stage breast cancer who meet clinical criteria, according to Syed. The technology can also greatly reduce the number of treatments compared with what is required with whole-breast radiation therapy.
